These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2106148)

  • 1. The effects of nigrostriatal 6-hydroxydopamine lesions on dopamine D2 receptor mRNA and opioid systems.
    Mansour A; Meador-Woodruff JH; Camp DM; Robinson TE; Bunzow J; Van Tol H; Civelli O; Akil H; Watson SJ
    Prog Clin Biol Res; 1990; 328():227-30. PubMed ID: 2106148
    [No Abstract]   [Full Text] [Related]  

  • 2. Substantia nigra 6-hydroxydopamine lesions alter dopaminergic synaptic markers in the nucleus basalis magnocellularis and striatum of rats.
    Geula C; Slevin JT
    Synapse; 1989; 4(3):248-53. PubMed ID: 2532792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term changes in striatal opioid systems after 6-hydroxydopamine lesion of rat substantia nigra.
    Smith JA; Leslie FM; Broide RS; Loughlin SE
    Neuroscience; 1993 Aug; 55(4):935-51. PubMed ID: 8232904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Localization of opiate receptors and enkephalins in the rat striatum in relationship with the nigrostriatal dopaminergic system: lesion studies.
    Pollard H; Llorens C; Schwartz JC; Gros C; Dray F
    Brain Res; 1978 Aug; 151(2):392-8. PubMed ID: 209865
    [No Abstract]   [Full Text] [Related]  

  • 5. Basal ganglia dopamine depletion does not alter D1 dopamine receptor binding properties.
    Trugman JM; Pronsky CJ; Wooten GF
    Adv Neurol; 1990; 53():107-10. PubMed ID: 2146858
    [No Abstract]   [Full Text] [Related]  

  • 6. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of striatal enkephalin turnover in rats receiving antagonists of specific dopamine receptor subtypes.
    Mocchetti I; Naranjo JR; Costa E
    J Pharmacol Exp Ther; 1987 Jun; 241(3):1120-4. PubMed ID: 3110407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhes, the Ras homolog enriched in striatum, is reduced under conditions of dopamine supersensitivity.
    Harrison LM; LaHoste GJ
    Neuroscience; 2006; 137(2):483-92. PubMed ID: 16352400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D-2 auto- and postsynaptic receptors in the nigrostriatal system of the rat brain: localization by quantitative autoradiography with [3H]sulpiride.
    Filloux FM; Wamsley JK; Dawson TM
    Eur J Pharmacol; 1987 Jun; 138(1):61-8. PubMed ID: 3113982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denervation supersensitivity of striatal D2 dopamine receptors is restricted to the ventro- and dorsolateral regions of the striatum.
    Savasta M; Dubois A; Feuerstein C; Manier M; Scatton B
    Neurosci Lett; 1987 Feb; 74(2):180-6. PubMed ID: 2883609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
    Brannan T; Knott P; Kaufmann H; Yahr M
    Adv Neurol; 1990; 53():75-81. PubMed ID: 2173378
    [No Abstract]   [Full Text] [Related]  

  • 13. Increase in striatal dopamine D2 receptor mRNA after lesions of haloperidol treatment.
    Coirini H; Schumacher M; Angulo JA; McEwen BS
    Eur J Pharmacol; 1990 Sep; 186(2-3):369-71. PubMed ID: 2127022
    [No Abstract]   [Full Text] [Related]  

  • 14. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localization of dopamine receptors in rat brain.
    Reisine TD; Nagy JI; Fibiger HC; Yamamura HI
    Brain Res; 1979 Jun; 169(1):209-14. PubMed ID: 455093
    [No Abstract]   [Full Text] [Related]  

  • 16. Partial reversal of increased preproenkephalin messenger ribonucleic acid (mRNA) and decreased preprotachykinin mRNA by foetal dopamine cells in unilateral 6-hydroxydopamine-lesioned rat striatum parallels functional recovery.
    Zeng BY; Jenner P; Marsden CD
    Mov Disord; 1996 Jan; 11(1):43-52. PubMed ID: 8771066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine and opiate receptors: localization in the striatum and evidence for their axoplasmic transport in the nigrostriatal and striatonigral pathways.
    Van der Kooy D; Weinreich P; Nagy JI
    Neuroscience; 1986 Sep; 19(1):139-46. PubMed ID: 2431346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nerve growth factor (NGF) potentiates the changes in striatal proenkephalin mRNAs subsequent to 6-hydroxydopamine-induced lesions of the substantia nigra.
    Cadet JL; Angulo JA; McEwen BS
    Brain Res Bull; 1990 Sep; 25(3):401-5. PubMed ID: 2127237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of dopamine metabolism in solid fetal substantia nigra transplants and their terminals in the host striatum.
    Meloni R; Gale K
    Prog Brain Res; 1990; 82():467-71. PubMed ID: 2127112
    [No Abstract]   [Full Text] [Related]  

  • 20. Nigrostriatal lesions enhance striatal 3H-apomorphine and 3H-spiroperidol binding.
    Creese I; Snyder SH
    Eur J Pharmacol; 1979 Jun; 56(3):277-81. PubMed ID: 38973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.